The analysis used records from the Shanghai Medical Database, a regional electronic medical record system, and followed patients across two periods. The researchers examined patient characteristics and treatment patterns during the year before an index date, then assessed disease burden during the following year. This design allowed the team to compare later outcomes between patients who were controlled and those who were already uncontrolled at baseline. Because the work was retrospective, the investigators did not assign treatments or monitor participants prospectively. Instead, they reconstructed patterns of care from existing records. Such databases can reveal how asthma behaves across thousands of real-world patients, including people who might be underrepresented in tightly managed clinical trials, but they also depend on the accuracy and completeness of routine medical documentation.

In the study, uncontrolled asthma was identified using evidence of exacerbations and specific treatment patterns recorded in the medical database. An exacerbation generally represents a clinically important worsening of airway inflammation and bronchial narrowing, often requiring additional medication or urgent medical attention. Asthma symptoms arise partly because inflamed airways become unusually sensitive and contract in response to triggers, while mucus production and swelling further restrict airflow. Inhaled corticosteroids are designed to suppress this underlying inflammation. LABAs work through a different mechanism: they stimulate β2-adrenergic receptors in airway smooth muscle, promoting relaxation and sustained bronchodilation. Combining the two classes can address both inflammation and airway constriction, but the need for medium-to-high doses does not guarantee that asthma will remain controlled.

The contrast between the two groups became particularly pronounced during follow-up. Among patients who were uncontrolled at baseline, 32.3% remained uncontrolled during the subsequent year. That compared with 10.7% among patients classified as controlled at baseline. The difference suggests that a history of poor control may be a powerful warning signal for future instability, even when patients are already receiving substantial inhaled therapy. The result does not prove that baseline uncontrolled asthma directly caused later deterioration, because the analysis was observational and patients with more severe disease may also have had other disadvantages. Nevertheless, the pattern is clinically important: a patient who continues to experience exacerbations or requires intensified treatment may need a more detailed reassessment rather than simply continuing the same prescription without investigation.

The burden extended beyond symptoms and prescriptions. During follow-up, 16.8% of patients who were uncontrolled at baseline received corticosteroids, compared with 3.9% of those who had been controlled. In this context, the finding reflects the treatment burden captured by the investigators’ outcome measures and points to more frequent need for anti-inflammatory rescue or intensified management. Repeated courses of systemic corticosteroids can be effective during severe flare-ups, but their cumulative use is associated with clinically important risks, including metabolic, bone and cardiovascular complications. The study’s data therefore highlight a central challenge in asthma care: inhaled treatment is intended to prevent attacks, while repeated escalation or reliance on additional corticosteroids may signal that prevention is not working adequately.

Acute-care use showed an even wider gap. Emergency-room visits and hospitalizations attributed to exacerbations occurred in 22.3% of the previously uncontrolled group, compared with 5.2% among those who were controlled at baseline. These encounters represent more than an increase in healthcare utilization. They indicate episodes in which airway narrowing and respiratory symptoms became serious enough to require urgent assessment or inpatient treatment. During a severe exacerbation, reduced airflow can develop rapidly as smooth muscle contraction, mucosal swelling and mucus obstruction combine to increase airway resistance. The sharp difference between the groups suggests that baseline control status could help identify people at elevated risk of acute events, potentially allowing clinicians to review inhaler technique, adherence, trigger exposure, comorbidities and the suitability of the treatment plan before the next crisis occurs.

The economic signal was smaller in relative terms but still measurable. Total medical costs during follow-up averaged 9,303.9 Chinese yuan for patients who were uncontrolled at baseline, compared with 8,621.4 yuan for those who were controlled. The difference is consistent with the clinical pattern observed in the records: emergency visits, hospital admissions, additional prescriptions and treatment for exacerbations can all add to the financial burden of asthma. The figures should not be interpreted as a universal estimate for every patient or healthcare system, because they came from a specific regional database and a defined period. They do, however, show how inadequate control can translate into costs even among patients already receiving medium-to-high intensity controller therapy.

The researchers also used multivariate logistic regression to identify factors associated with adverse outcomes during follow-up. This statistical approach estimates the relationship between several patient or treatment characteristics and a binary outcome while adjusting for other variables included in the model. It can help distinguish a factor that remains associated with poor outcomes after accounting for measured differences between patients from one that merely reflects another underlying characteristic. Regression cannot eliminate confounding, however, and it cannot establish that any associated factor causes an asthma outcome. Important details may also be absent from electronic records, including whether patients used inhalers correctly, took medication consistently, encountered indoor or occupational allergens, smoked, or had coexisting conditions such as chronic rhinosinusitis, obesity or gastroesophageal reflux.

The study’s central message is therefore not that medium-to-high dose ICS or ICS/LABA therapy fails, but that treatment intensity alone is an incomplete measure of asthma control. When patients continue to experience exacerbations despite controller medication, clinicians may need to verify the diagnosis, assess adherence and inhaler technique, identify modifiable exposures and evaluate conditions that worsen respiratory symptoms. Some patients may require specialist review or additional therapies, while others may improve when practical barriers to regular treatment are addressed. By documenting the outcomes of 35,900 patients in routine care, the analysis places a striking number on a familiar clinical problem: nearly one in three people treated at these medication levels was uncontrolled at baseline, and that group faced substantially higher risks during the following year. The findings reinforce the need for early recognition of instability, closer follow-up after exacerbations and treatment decisions guided by actual disease behavior rather than prescription records alone.